WHO 2016 DEFINITION OF CHRONIC MYELOID LEUKEMIA AND TYROSINE KINASE INHIBITORS
Philadelphia (Ph*)/ BCR-ABL1 positive-chronic myeloid leukemia (CML) shall be considered as a chronic life-long disease, which could be manageable with Tyrosine Kinase Inhibitor (TKI) drugs. The target of TKI drug treatment is to provide age- and sex-matched duration of life in a given patient with CML. Personalized CML treatment with TKI drugs is the key strategy regarding the harmonization of CML disease characteristics, clinical experience and best clinical evidence. Specific CML disease characteristics in a given patient include CML disease risk, comorbidities, molecular profile, compliance, life style, and drug off-target risk profile. CML research evidence includes randomized clinical trials indicating the data on the safety, efficacy, tolerability, toxicity, possible long-term adverse events and cost of TKI. Clinics and physician experience include TKI availability, TKI reimbursability, drug experience, adherence, and BCR-ABL1 monitorization facility. Key decision choosing of TKI for CML should be made via the consideration of those variables. The aim of this paper is to outline WHO-2016 defined CML and its proper management with TKI drugs.